osimertinib
astrazeneca
['nsclc', 'sclc', 'osimertinib', 'lcsm,(-blcsm)', 'adaura']
hard to argue with updated #adaura dfs data presented at #esmo22 making adjuvant osimertinib soc for egfr-mutated, resected nsclc (strongest benefit for stage ii-iii) osi mdfs 65.8 mos vs 21.9 mos (hr 0.23; 95% ci, 0.18-0.30). via #lcsm
Associate Director Community Outreach- Thoracic Oncology-University of Miami @SylvesterCancer , Boricua en la Luna, Tweets are my own. (she/her)